The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Open accessAbstract
BACKGROUND: Pharmacologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease. The effect of lowering low-density lipoprotein (LDL) cholesterol levels by inhibiting PCSK9 on the risk of cardiovascular events or diabetes is unknown. METHODS: We used genetic scores consisting of independently inherited variants in the genes encoding PCSK9 and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; the target of statins) as instruments to randomly assign 112,772 participants from 14 studies, with 14,120 cardiovascular events and 10,635 cases of diabetes, to groups according to the number of LDL cholesterol-lowering alleles that they had inherited. We compared the effects of lower LDL cholesterol levels that were mediated by variants in PCSK9, HMGCR, or both on the risk of cardiovascular events and the risk of diabetes. RESULTS: Variants in PCSK9 and HMGCR were associated with nearly identical protective effects on the risk of cardiovascular events per decrease of 10 mg per deciliter (0.26 mmol per liter) in the LDL cholesterol level: odds ratio for cardiovascular events, 0.81 (95% confidence interval [CI], 0.74 to 0.89) for PCSK9 and 0.81 (95% CI, 0.72 to 0.90) for HMGCR. Variants in these two genes were also associated with very similar effects on the risk of diabetes: odds ratio for each 10 mg per deciliter decrease in LDL cholesterol, 1.11 (95% CI, 1.04 to 1.19) for PCSK9 and 1.13 (95% CI, 1.06 to 1.20) for HMGCR. The increased risk of diabetes was limited to persons with impaired fasting glucose levels for both scores and was lower in magnitude than the protective effect against cardiovascular events. When present together, PCSK9 and HMGCR variants had additive effects on the risk of both cardiovascular events and diabetes. CONCLUSIONS: In this study, variants in PCSK9 had approximately the same effect as variants in HMGCR on the risk of cardiovascular events and diabetes per unit decrease in the LDL cholesterol level. The effects of these variants were independent and additive. (Funded by the Medical Research Council and the National Heart, Lung, and Blood Institute.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As an extension of MR, drug target MR has emerged as efficient way to estimate therapeutic potential by using genetic variants in genes encoding drug targets (referred to as cis variants) to mimic the actions of drugs.”
From Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study (2025) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Likewise, these observations are supported by data from a recent mendelian randomization study in which variants in PCSK9 and variants in HMGCR were associated with nearly identical lower risks of cardiovascular events per unit reduction in LDL cholesterol.29”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [29]
In the citing paper
“mendelian randomisation studies 8,[19][20][21] of genetic polymorphisms that mimic the effects of statins, ezetimibe, or PCSK9 inhibitors suggest that lifelong reductions in LDL cholesterol, irrespective of the mechanism, are associated with an increased risk of diabetes.”
In the citing paper
“Mendelian randomisation analyses 8,20,21 have shown that genetically determined loss of function of PCSK9 is associated with an increased risk of incident diabetes, but clinical trials of PCSK9 inhibitors have shown no such effect.9”
In the citing paper
“Therefore, the clinical benefit of therapies that lower LDL-C by reducing LDL particle mass will be proportional to the absolute reduction in LDLC, because-on average-the reduction in LDL-C and LDL particles will be concordant [34,50,54,55].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Genetic studies of body mass index yield new insights for obesity biology
Study, T. L. C., Locke, A. E., The ADIPOGen Consortium, The AGEN-BMI Working Group, The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The, G. L. G. C., The, I. C. B. P., The MAGIC Investigators, The MuTHER Consortium, et al. (2015) · Nature · doi:10.1038/nature14177 · Cited by 4,534
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citationMulti-Ethnic Study of Atherosclerosis: Objectives and Design
Bild, D. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf113 · Cited by 3,942
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Willer (2013) · doi:10.1038/ng.2797 · Cited by 2,983
A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease
the CARDIoGRAMplusC4D Consortium (2015) · Nature Genetics · doi:10.1038/ng.3396 · Cited by 2,447
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 747
Strategies to Overcome Residual Risk During Statins Era
Cho, K. I., Yu, J., Hayashi, T., Han, S. H., & Koh, K. K. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0624 · Cited by 39
Natarajan, P., Pampana, A., Graham, S. E., Ruotsalainen, S., Perry, J. A., de Vries, P. S., Broome, J., Pirruccello, J. P., Honigberg, M. C., Aragam, K. G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22339-1 · Cited by 36
Cholesterol Metabolism in Chronic Kidney Disease: Physiology, Pathologic Mechanisms, and Treatment
Pan, X. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-0394-6_9 · Cited by 39
Dutka, M., Zimmer, K., Ćwiertnia, M., Ilczak, T. P., & Bobiński, R. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10409-7 · Cited by 46
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients
Nicholls, S. J., Nelson, A. J., Ray, K. K., Ballantyne, C. M., Ditmarsch, M., Kling, D. F., Hsieh, A., Szarek, M. J., Kastelein, J. J. P., & Davidson, M. H. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.056 · Cited by 39
Carter, P., Vithayathil, M. K., Kar, S., Potluri, R., Mason, A. M., Larsson, S. C., & Burgess, S. (2020) · eLife · doi:10.7554/elife.57191 · Cited by 38
Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran
Wilkinson, M. J., Bajaj, A., Brousseau, M. E., & Taub, P. R. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032031 · Cited by 37
Alirocumab for the treatment of hypercholesterolemia
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1305354 · Cited by 37
Peyot, M., Roubtsova, A., Lussier, R., Chamberland, A., Essalmani, R., Madiraju, S. R. M., Seidah, N. G., Prentki, M., & Prat, A. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.158968 · Cited by 39
Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study
Goldman, A., Raschi, E., Cukierman‐Yaffe, T., Dankner, R. S., Shouval, R., Shechter, M., Ben‐Zvi, I., Gerstein, H. C., & Maor, E. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab209 · Cited by 38
Chasing LDL cholesterol to the bottom — PCSK9 in perspective
Libby, P., & Tokgözoğlu, L. S. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00085-x · Cited by 41
Contribution of Common Genetic Variants to Risk of Early-Onset Ischemic Stroke
Jaworek, T. J., Xu, H., Gaynor, B. J., Cole, J. W., Rannikmäe, K., Stanne, T. M., Tomppo, L., Abedi, V., Amouyel, P., Armstrong, N. D., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201006 · Cited by 37
A Genetic Approach to the Association Between PCSK9 and Sepsis
Feng, Q., Wei, W., Chaugai, S., Leon, B. G. C., Kawai, V. K., Leon, D. A. C., Jiang, L., Zhong, X. Y., Liu, G., Ihegword, A., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.11130 · Cited by 35
Evaluation of the Pleiotropic Effects of Statins
Labos, C., Brophy, J. M., Smith, G. D., Sniderman, A. D., & Thanassoulis, G. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310052 · Cited by 36
Safety and Tolerability of PCSK9 Inhibitors: Current Insights
Kosmas, C. E., Skavdis, A., Sourlas, A., Papakonstantinou, E. J., Genao, E. P., Uceta, R. E., & Guzman, E. (2020) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s288831 · Cited by 53
Yeung, S. L. A., Borges, M. C., Wong, T. H. T., Lawlor, D. A., & Schooling, C. M. (2022) · International Journal of Epidemiology · doi:10.1093/ije/dyac212 · Cited by 35
Baragetti, A., Grejtáková, D., Casula, M., Olmastroni, E., Jotti, G. S., Norata, G. D., Catapano, A. L., & Bellosta, S. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.025 · Cited by 35
Self-citationUeng, K., Chiang, C., Chao, T., Wu, Y., Lee, W.-L., Li, Y., Ting, K.-H., Su, C.-H., Lin, H., Su, T., et al. (2023) · PubMed Central · doi:10.6515/acs.202301_39(1).20221103a · Cited by 34
Leiter, L. A., Müller‐Wieland, D., Baccara‐Dinet, M. T., Letierce, A., Samuel, R., & Cariou, B. (2017) · Diabetic Medicine · doi:10.1111/dme.13450 · Cited by 33
Statins and New-Onset Diabetes Mellitus: LDL Receptor May Provide a Key Link
Yu, Q., Chen, Y., & Xu, C. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00372 · Cited by 33
Pancreatic PCSK9 controls the organization of the β-cell secretory pathway via LDLR-cholesterol axis
Marku, A., Dalt, L. D., Galli, A., Dule, N., Corsetto, P. A., Rizzo, A. M., Moregola, A., Uboldi, P., Bonacina, F., Marciani, P., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155291 · Cited by 36
Self-citationStatin use and risk for type 2 diabetes: what clinicians should know
Maki, K. C., Diwadkar‐Navsariwala, V., & Kramer, M. W. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2018.1402658 · Cited by 32
Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients
Hwang, H. S., Kim, J. S., Kim, Y., Lee, S., Ahn, S. Y., Lee, H. J., Lee, D.-Y., Lee, S. H., Moon, J.-Y., & Jeong, K. H. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010244 · Cited by 33
Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.964 · Cited by 35
PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
Jia, X., Rifai, M. A., Saeed, A., Ballantyne, C. M., & Virani, S. S. (2022) · Vascular Health and Risk Management · doi:10.2147/vhrm.s275739 · Cited by 34
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Masuda, S., Miyagawa, S., & Sawa, Y. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1703361 · Cited by 33
Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes
Ramin‐Mangata, S., Wargny, M., Pichelin, M., May, C. L., Thedrez, A., Blanchard, V., Nativel, B., Santos, R. D., Benseñor, I. M., Lotufo, P. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.11.027 · Cited by 33
Anti-HMGCR myopathy: clinical and histopathological features, and prognosis
Kurashige, T. (2021) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000832 · Cited by 31
Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes
Croyal, M., Wargny, M., Chemello, K., Chevalier, C., Blanchard, V., Bigot‐Corbel, E., Lambert, G. C., May, C. L., Hadjadj, S., & Cariou, B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01452-5 · Cited by 32
PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
Hadjiphilippou, S., & Ray, K. K. (2017) · Heart · doi:10.1136/heartjnl-2016-310844 · Cited by 30
PCSK9 Inhibitors in Secondary Prevention—An Opportunity for Personalized Therapy
Chase Board, Kelly, M. S., Shapiro, M. D., & Dixon, D. L. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000809 · Cited by 30
IL6 genetic perturbation mimicking IL-6 inhibition is associated with lower cardiometabolic risk
Zhang, L., Omarov, M., Xu, L., deGoma, E. M., Natarajan, P., & Georgakis, M. K. (2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00700-7 · Cited by 32
Müller‐Wieland, D., Leiter, L. A., Cariou, B., Letierce, A., Colhoun, H. M., Prato, S. D., Henry, R. R., Tinahones, F. J., Aurand, L. A., Maroni, J. M., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0552-4 · Cited by 30
Poor attainment of lipid targets in patients with symptomatic peripheral artery disease
Dopheide, J. F., Papac, L., Schindewolf, M., Baumgärtner, I., & Drexel, H. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.02.013 · Cited by 29
Gonna, H., & Ray, K. K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13691 · Cited by 30
LDL-C plays a causal role on T2DM: a Mendelian randomization analysis
Pan, W., Sun, W., Yang, S., Zhuang, H., Jiang, H., Ju, H., Wang, D., & Han, Y. (2020) · Aging · doi:10.18632/aging.102763 · Cited by 31
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 32
Cardiovascular events, diabetes and guidelines: the virtue of simplicity
Esper, R. J., & Nordaby, R. A. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0844-y · Cited by 30
Causal Effect of Lipids and Lipoproteins on Atherosclerosis
Ference, B. A. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.001 · Cited by 28
Self-citationMendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations
Hu, Q., Hao, P., Liu, Q., Dong, M., Gong, Y., Zhang, C., & Zhang, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9537-4 · Cited by 30
Gormley, M., Yarmolinsky, J., Dudding, T., Burrows, K., Martin, R. M., Thomas, S. J., Tyrrell, J., Brennan, P., Pring, M., Boccia, S., et al. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009525 · Cited by 32
Ramin‐Mangata, S., Thedrez, A., Nativel, B., Diotel, N., Blanchard, V., Wargny, M., Aguesse, A., Billon‐Crossouard, S., Vindis, C., May, C. L., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.044 · Cited by 29
Safety of Statins and Nonstatins for Treatment of Dyslipidemia
Newman, C. B. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.01.004 · Cited by 32
The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease
Mehta, N. N., Dangas, K., Ditmarsch, M., Rensen, P. C. N., Dicklin, M. R., & Kastelein, J. J. P. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106972 · Cited by 28
Familial Hypercholesterolemia and Type 2 Diabetes in the Old Order Amish
Xu, H., Ryan, K. A., Jaworek, T. J., Southam, L., Reid, J. G., Overton, J. D., Baras, A., Puurunen, M. K., Zeggini, E., Taylor, S. I., et al. (2017) · Diabetes · doi:10.2337/db17-0173 · Cited by 28
Ginsberg, H. N., Farnier, M., Robinson, J. G., Cannon, C. P., Sattar, N. A., Baccara‐Dinet, M. T., Letierce, A., Bujas‐Bobanovic, M., Louie, M. J., & Colhoun, H. M. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0439-8 · Cited by 28
Self-citationvan Loon, N. M., Ottenhoff, R., Kooijman, S., Moeton, M., Scheij, S., Roscam Abbing, R. L. P., Gijbels, M. J. J., Levels, J. H. M., Sorrentino, V., Berbée, J. F. P., et al. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.311168 · Cited by 25
A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR
Safarova, M. S., Satterfield, B. A., Fan, X., Austin, E. E., Ye, Z., Bastarache, L. A., Zheng, N. S., Ritchie, M. D., Borthwick, K. M., Williams, M. S., et al. (2019) · npj Genomic Medicine · doi:10.1038/s41525-019-0078-7 · Cited by 29
Proprotein convertase subtilisin/kexin type 9 in kidney disease
Schmit, D., Fliser, D., & Speer, T. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz122 · Cited by 28
Pérez‐Calahorra, S., Civeira, F., Guallar‐Castillón, P., Pintó, X., Banegas, J. R., Pedro‐Botet, J., Tembra, M. S., Mauri, M., Soler, C., Rodríguez‐Artalejo, F., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319896138 · Cited by 29
Furtado, R. H. M., & Giugliano, R. P. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00163-w · Cited by 29
Self-citationRath, A. A., Lam, H. S., & Schooling, C. M. (2021) · European Journal of Clinical Nutrition · doi:10.1038/s41430-021-00882-w · Cited by 28
Using Human ‘Experiments of Nature’ to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors
Jerome, R. N., Pulley, J. M., Roden, D. M., Shirey-Rice, J. K., Bastarache, L. A., Bernard, G. R., Ekstrom, L. B., Lancaster, W. J., & Denny, J. C. (2017) · Drug Safety · doi:10.1007/s40264-017-0616-0 · Cited by 29
Sivashanmugarajah, A. S., Fulcher, J., SULLIVAN, D. R., Elam, M. B., Jenkins, A. J., & KEECH, A. C. (2019) · Internal Medicine Journal · doi:10.1111/imj.14429 · Cited by 26
Li, Z., Ye, C., Zhao, T., & Yang, L. (2020) · BMC Public Health · doi:10.1186/s12889-020-09130-5 · Cited by 31
The Role of Statins in Current Guidelines
Rached, F. H., & Santos, R. D. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00861-9 · Cited by 30
Targeting low‐density lipoprotein cholesterol with PCSK9 inhibitors
Scherer, D. J., Nelson, A. J., Psaltis, P. J., & Nicholls, S. J. (2017) · Internal Medicine Journal · doi:10.1111/imj.13451 · Cited by 27
Gai, M., Adi, D., Chen, X., Liu, F., Xie, X., Yang, Y., Gao, X., Ma, X., Fu, Z.-Y., Ma, Y.-T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90975-0 · Cited by 28
Inclisiran: How Widely and When Should We Use It?
Pirillo, A., & Catapano, A. L. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01056-0 · Cited by 27
Self-citationBoccara, F., Ghislain, M., Meyer, L., Goujard, C., May, C. L., Vigouroux, C., Bastard, J. P., Fellahi, S., Capeau, J., Cohen, A. A., et al. (2017) · AIDS · doi:10.1097/qad.0000000000001633 · Cited by 26
CETP‐Inhibition and HDL‐Cholesterol: A Story of CV Risk or CV Benefit, or Both
Nicholls, S. J. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1118 · Cited by 25
Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials
Leiter, L. A., Tinahones, F. J., Karalis, D. G., Bujas‐Bobanovic, M., Letierce, A., Mandel, J., Samuel, R., & Jones, P. H. (2018) · Diabetic Medicine · doi:10.1111/dme.13817 · Cited by 26
Reprint of: Impact of Lipids on Cardiovascular Health
Ference, B. A., Graham, I. M., Tokgözoğlu, L. S., & Catapano, A. L. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.021 · Cited by 26
Self-citationIncreasing Lipolysis and Reducing Atherosclerosis
Tall, A. R. (2017) · New England Journal of Medicine · doi:10.1056/nejme1706907 · Cited by 26
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
Goodman, S. G., Steg, P. G., Szarek, M. J., Bhatt, D. L., Bittner, V., Díaz, R., Harrington, R. A., Jukema, J. W., White, H. D., Zeiher, A. M., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae025 · Cited by 27
A New Approach to PCSK9 Therapeutics
Wang, N., & Tall, A. R. (2017) · Circulation Research · doi:10.1161/circresaha.117.310610 · Cited by 27
Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease
Emdin, C. A., Klarin, D. M., Natarajan, P., Florez, J. C., Kathiresan, S., & Khera, A. V. (2017) · Diabetes · doi:10.2337/db17-0149 · Cited by 24
Page, M. M., & Watts, G. F. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13070 · Cited by 27
Smit, R. A. J., Trompet, S., Leong, A., Goodarzi, M. O., Postmus, I., Warren, H. R., Theusch, E., Barnes, M. R., Arsenault, B. J., Li, X., et al. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0125-x · Cited by 26
Nakamura, A., Kanazawa, M., Kagaya, Y., Kondo, M., Sato, K., Endo, H., & Nozaki, E. (2020) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.04.006 · Cited by 25
Chiu, S., Pratt, C. M., Feinn, R., & Chatterjee, S. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420924983 · Cited by 26
Bays, H. E., Baum, S. J., Brinton, E. A., Plutzky, J., Hanselman, J. C., Teng, R., & Ballantyne, C. M. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100278 · Cited by 25
Wang, K., Shi, M., Huang, C., Fan, B., Luk, A. O. Y., Kong, A. P. S., Ronald, C. W., Chan, J. C. N., & Chow, E. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01613-6 · Cited by 25
Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review
Chang, Y., Eom, S., Kim, M.-J., & Song, T. (2023) · Medicina · doi:10.3390/medicina59040776 · Cited by 25
Bococizumab for the treatment of hypercholesterolaemia
Ferri, N., Corsini, A., Sirtori, C. R., & Ruscica, M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1279602 · Cited by 24
Liu, G., Shi, M., Mosley, J. D., Weng, C., Zhang, Y., Lee, M. T. M., Jarvik, G. P., Hakonarson, H. H., Namjou‐Khales, B., Abou‐Sleiman, P. M., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.12820 · Cited by 24
Koh, K. K., Sakuma, I., Shimada, K., Hayashi, T., & Quon, M. J. (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.0406 · Cited by 24
Efficacy and safety of PCSK9 monoclonal antibodies
Iqbal, Z., Dhage, S. S., Mohamad, J. B., Abdel-Razik, A. E. S., Donn, R. P., Malik, R. A., Ho, J. H., Liu, Y., Adam, S., Isa, B., et al. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1681395 · Cited by 26
The Inherited Basis of Coronary Artery Disease
Schunkert, H., Natarajan, P., & Samani, N. J. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2405153 · Cited by 23
Human genetics as a model for target validation: finding new therapies for diabetes
Thomsen, S. K., & Gloyn, A. L. (2017) · Diabetologia · doi:10.1007/s00125-017-4270-y · Cited by 24
Best Treatment Strategies With Statins to Maximize the Cardiometabolic Benefits
Cho, K. I., Sakuma, I., Sohn, I. S., Hayashi, T., Shimada, K., & Koh, K. K. (2018) · Circulation Journal · doi:10.1253/circj.cj-17-1445 · Cited by 23
Genetics of Type 2 Diabetes: Opportunities for Precision Medicine
Kim, D. S., Gloyn, A. L., & Knowles, J. W. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.03.346 · Cited by 25
Obesity Partially Mediates the Diabetogenic Effect of Lowering LDL Cholesterol
Wu, P., Moon, J., Daghlas, I., Giulianini, F., Porneala, B., Ahmadizar, F., Richardson, T. G., Isaksen, J. L., Hindy, G., Yao, J., et al. (2021) · Diabetes Care · doi:10.2337/dc21-1284 · Cited by 24
Sobczyk, M., Zheng, J., Smith, G. D., & Gaunt, T. R. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-072087 · Cited by 26
Muzammil, K., Hooshiar, M. H., Varmazyar, S., Omar, T. M., Karim, M. M., Aadi, S., Kalavi, S., & Yasamineh, S. (2024) · Microbial Cell Factories · doi:10.1186/s12934-024-02355-8 · Cited by 24
RetractedCyr, Y., Bissonnette, S., Lamantia, V., Wassef, H., Loizon, E., Sock, E. T. N., Vidal, H., Mayer, G., Chrétien, M., & Faraj, M. (2020) · Obesity · doi:10.1002/oby.22985 · Cited by 24
Impact of PCSK9 inhibitors in glycaemic control and new-onset diabetes
González-Lleó, A. M., Sánchez-Hernández, R. M., Plana, N., Ibarretxe, D., Rehues, P., Ribalta, J., Llop, D., Wägner, A. M., Masana, L., & Boronat, M. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02077-y · Cited by 23
Ballantyne, C. M., & Norata, G. D. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf606 · Cited by 23
Colesterol LDL, cuanto más bajo mejor
Pedro‐Botet, J., & Pintó, X. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.10.003 · Cited by 23
Landmesser, U., Lindgren, P., Hagström, E., van Hout, B., Villa, G., Pemberton-Ross, P. J., Arellano, J., Svensson, M. K. E., Sibartie, M., & Fonarow, G. C. (2020) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaa072 · Cited by 22
Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?
Rossini, E., Biscetti, F., Rando, M. M., Nardella, E., Cecchini, A. L., Nicolazzi, M. A., Covino, M., Gasbarrini, A., Massetti, M., & Flex, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169326 · Cited by 25
Hsu, L., Teng, M., Wu, S., Chou, H., & Ko, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810418 · Cited by 21
Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?
Filippatos, T. D., Christopoulou, E. C., & Elisaf, M. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000523 · Cited by 22
Faraj, M. (2020) · Journal of Biomedical Research · doi:10.7555/jbr.34.20190124 · Cited by 23
Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL Cholesterol
Newman, C. B., & Tobert, J. A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac708 · Cited by 20
Lamantia, V., Bissonnette, S., Beaudry, M., Cyr, Y., Rosiers, C. D., Baass, A. W., & Faraj, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-73672-6 · Cited by 24
Chen, Q., Wu, G., Li, C., Qin, X., Liu, R., & Zhang, M. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00386-w · Cited by 22
Ali, L., Cupido, A. J., Rijkers, M., Hovingh, G. K., Holleboom, A. G., Dallinga‐Thie, G. M., Stroes, E. S. G., & van den Boogert, M. A. W. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.07.001 · Cited by 21
A phenome-wide association study of genetically mimicked statins
Li, S., & Schooling, C. M. (2021) · BMC Medicine · doi:10.1186/s12916-021-02013-5 · Cited by 20
Cardiomyocyte-specific PCSK9 deficiency compromises mitochondrial bioenergetics and heart function
Laudette, M., Lindbom, M., Arif, M., Cinato, M., Ruiz, M., Doran, S., Miljanovic, A., Rutberg, M., Andersson, L. K., Klevstig, M., et al. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad041 · Cited by 21
Metadata
- Authors
- Ference, B. A., Robinson, J. G., Brook, R. D., Catapano, A. L., Chapman, M. J., Neff, D. R., Voros, S., Giugliano, R. P., Davey Smith, G., Fazio, S., & Sabatine, M. S.
- Affiliations
- University of Iowa (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12
- Volume
- 375
- Issue
- 22
- Pages
- 2144-2153
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2557654447
- Cited by
- 743
- References
- 39
- Citations by year
- 2026: 38 · 2025: 55 · 2024: 77 · 2023: 64 · 2022: 74 · 2021: 76 · 2020: 75 · 2019: 86 · 2018: 97 · 2017: 92 · 2016: 8
- FWCI
- 104.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Bristol Research (University of Bristol) (submittedVersion, other-oa)
- Funders
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- PCSK9, HMGCR, LDL cholesterol, cardiovascular disease, diabetes mellitus, genetic variants, PCSK9 inhibitors, statins, genetic score, impaired fasting glucose, additive genetic effects, cardiovascular risk prediction, LDL-C lowering therapy, HMG-CoA reductase inhibition, cardiovascular events, diabetes risk
- MeSH terms
- Proprotein Convertase 9, Cardiovascular Diseases, Diabetes Mellitus, Female, Humans, Hydroxymethylglutaryl CoA Reductases, Cholesterol, LDL, Male, Middle Aged, Random Allocation, Risk, Genetic Variation, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
